Geno J. Germano
CIK: 0001424383
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Oct 19, 2026ELOX
Eloxx Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
13.6K shares- - Sep 25, 2026DTIL
PRECISION BIOSCIENCES INC
Purchase(P)Direct2.6K shares at avg. $6.28$16K - Aug 7, 2026ENTX
Entera Bio Ltd.
Award(A)Direct25K shares- - Jun 3, 2026DTIL
PRECISION BIOSCIENCES INC
Award(A)DirectRestricted Stock Units
21K shares- - May 20, 2026DTIL
PRECISION BIOSCIENCES INC
Exercise(M)Direct21K shares- - May 14, 2026HRMY
Harmony Biosciences Holdings, Inc.
Award(A)DirectStock Option
21.2K shares- - Mar 9, 2026ENTX
Entera Bio Ltd.
Purchase(P)Direct20K shares at avg. $1.30$26K - Feb 10, 2026ENTX
Entera Bio Ltd.
Purchase(P)Direct20K shares at avg. $1.49$30K - Dec 16, 2025DTIL
PRECISION BIOSCIENCES INC
Purchase(P)Direct3K shares at avg. $4.72$14K - Jul 31, 2025SAGE
Sage Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
21.5K shares- - Jun 11, 2025SAGE
Sage Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
21.5K shares- - Jun 3, 2025DTIL
PRECISION BIOSCIENCES INC
Award(A)DirectRestricted Stock Units
21K shares- - May 27, 2025DTIL
PRECISION BIOSCIENCES INC
Exercise(M)Direct9.8K shares- - Mar 25, 2025DTIL
PRECISION BIOSCIENCES INC
Purchase(P)Direct3.3K shares at avg. $5.30$17K - Dec 30, 2024DTIL
PRECISION BIOSCIENCES INC
Purchase(P)Direct3.6K shares at avg. $4.49$16K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 19, 2026 |  ELOX Eloxx Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 13,587 | - | - | Direct |
| Sep 25, 2026 |  DTIL PRECISION BIOSCIENCES INC | Purchase(P) | 2,609 | $6.28 | $16,385 | Direct |
| Aug 7, 2026 |  ENTX Entera Bio Ltd. | Award(A) | 25,014 | - | $0 | Direct |
| Jun 3, 2026 | DTIL PRECISION BIOSCIENCES INC | Award(A) Restricted Stock Units | 20,979 | - | - | Direct |
| May 20, 2026 | DTIL PRECISION BIOSCIENCES INC | Exercise(M) | 21,000 | - | $0 | Direct |
| May 14, 2026 |  HRMY Harmony Biosciences Holdings, Inc. | Award(A) Stock Option | 21,231 | - | - | Direct |
| Mar 9, 2026 | ENTX Entera Bio Ltd. | Purchase(P) | 20,000 | $1.30 | $26,000 | Direct |
| Feb 10, 2026 | ENTX Entera Bio Ltd. | Purchase(P) | 20,000 | $1.49 | $29,800 | Direct |
| Dec 16, 2025 | DTIL PRECISION BIOSCIENCES INC | Purchase(P) | 3,000 | $4.72 | $14,160 | Direct |
| Jul 31, 2025 |  SAGE Sage Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 21,500 | - | - | Direct |
| Jun 11, 2025 | SAGE Sage Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 21,500 | - | - | Direct |
| Jun 3, 2025 | DTIL PRECISION BIOSCIENCES INC | Award(A) Restricted Stock Units | 21,000 | - | - | Direct |
| May 27, 2025 | DTIL PRECISION BIOSCIENCES INC | Exercise(M) | 9,826 | - | - | Direct |
| Mar 25, 2025 | DTIL PRECISION BIOSCIENCES INC | Purchase(P) | 3,250 | $5.30 | $17,225 | Direct |
| Dec 30, 2024 | DTIL PRECISION BIOSCIENCES INC | Purchase(P) | 3,605 | $4.49 | $16,186 | Direct |
1-15 of 15 transactions
About Germano Geno J
Germano Geno J (SEC CIK 0001424383) files insider reports with the SEC as Director of Eloxx Pharmaceuticals, Inc. (ELOX), Director of PRECISION BIOSCIENCES INC (DTIL) and Director of Entera Bio Ltd. (ENTX). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 17 ownership filings by Germano Geno J (3 Form 3, 14 Form 4), filed between Jan 2, 2025 and Oct 21, 2026. Those filings report 15 transactions, from Dec 30, 2024 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Germano Geno J's filings is in ARLINGTON, MA.
Recent filings by Germano Geno J
- Oct 19, 2026: Grant or award of ELOX derivative securities (Form 4, code A).
- Sep 25, 2026: Open-market purchase of DTIL shares (Form 4, code P).
- Aug 7, 2026: Grant or award of ENTX shares (Form 4, code A).
- Jun 3, 2026: Grant or award of DTIL derivative securities (Form 4, code A).
- May 20, 2026: Option exercise of DTIL shares (Form 4, code M).
Other insiders filing for Eloxx Pharmaceuticals, Inc. (ELOX)
- Domicilium Real Estate Fund III LP, 10% Owner
- Webster Stephen W, Director
- Walts Alan Edmund, Director
- Kjellson Nina S, Director
- Aggarwal Sumit, President and CEO
- Rubin Steven D, Director